CWG
NKTR icon

C WorldWide Group’s Nektar Therapeutics NKTR Stock Holding History

C WorldWide Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5,398
Closed -$4.94M – 131
2018
Q3 		$4.94M Buy
+5,398
New +$4.61M 0.06% 65

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

C WorldWide Group's NKTR Position: Q4 2018 in Review

C WorldWide Group sold out of Nektar Therapeutics (NKTR) in Q4 2018, closing a stake of 5,398 shares — an estimated $4.94M sold.

C WorldWide Group first reported a position in NKTR in Q3 2018 and held it in 1 quarter. The position peaked at $4.94M in Q3 2018. 343 funds tracked by Wall St. Rank hold NKTR as of Q4 2018.

  • C WorldWide Group reported no remaining Nektar Therapeutics position as of Q4 2018 after selling out during the quarter.
  • C WorldWide Group sold 5,398 Nektar Therapeutics shares in Q4 2018, an estimated $4.94M.
  • C WorldWide Group first reported a position in Nektar Therapeutics in Q3 2018 and held it in 1 quarter.
  • C WorldWide Group's Nektar Therapeutics position peaked at $4.94M in Q3 2018.
  • 343 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2018.

Based on C WorldWide Group's 13F filing for Q4 2018, filed 12 Feb 2019.